Better Buy: CVS Stock or UnitedHealth Stock?
2 extracted signals · 0 resolved · 2 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 16 Aug 2026, 16:15 UTC
- Recorded by Tahlil Plus
- 16 Aug 2026, 17:50 UTC
AI-generated source summary
The analysis compares CVS Health and UnitedHealth Group (UNH) based on revenue, operating margin, and return on invested capital. Both companies show revenue growth, but UnitedHealth Group has consistently generated more revenue. However, CVS Health's operating margin has been declining from around 7% in 2017 to 4.82% in the most recent update, while UnitedHealth's has also seen a decline from approximately 8% to 3.54%. Both companies are experiencing a decline in return on invested capital, with CVS Health's ROC dropping to 3.12% and UnitedHealth's to 8.13%. In terms of valuation, CVS Health trades at a forward P/E of 11.12, while UnitedHealth Group trades at 17.79. Based on a discounted cash flow model, the fair value of CVS Health is estimated at $111.28 per share, compared to its current market price of $94.52, suggesting it is undervalued. UnitedHealth Group's fair value is estimated at $1030, with a current market price of $1150, suggesting it is overvalued. Despite the lower operating margins and ROC for CVS, its lower valuation and perceived undervaluation make it a more attractive investment. The analysis suggests a bullish outlook for CVS and a potentially bearish outlook for UNH due to these factors.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
2 signals remain active.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.